Table 1.
Center 1 cohort description.
| Patient characteristics of cohorts from center 1 | ||
|---|---|---|
| Mutation prediction | Recurrence prediction | |
| Gender, n (%) | N = 1233 | N = 305 |
| Male | 661 (54%) | 180 (59.0%) |
| Female | 572 (46%) | 125 (41.0%) |
| Age, years | ||
| Median | 66 | 64 |
| Range | 19–97 | 19–97 |
| Type of sampling | ||
| Tumor resection | 1002 (81.3%) | 244 (80.0%) |
| Open biopsy | 42 (3.2%) | 10 (3.3%) |
| Core needle biopsy | 191 (15.5%) | 51 (16,7%) |
| Tumor site | ||
| Gastric | 677 (54.9%) | 167 (54.8%) |
| Small intestine | 357 (29.0%) | 97 (31.8%) |
| Colon or rectum | 53 (4.3%) | 13 (4.3%) |
| NA | 14 (1.1%) | 4 (1,3%) |
| Others | 132 (10.7%) | 24 (7.8%) |
| Type of tumor cell | ||
| Spindle | 716 (58.0%) | |
| Epithelioid | 351 (28.5%) | |
| Mixt | 166 (13.5%) | |
| Mutated exon | ||
| KIT exon 11 | 758 (61.5%) | 180 (59.0%) |
| KIT exon 9 | 101 (8.2%) | 30 (9.8%) |
| PDGFRA exon 18 | 173 (14.0%) | 35 (11.5%) |
| Wild type | 130 (10.5%) | 38 (12.5%) |
| Others | 71 (5.8%) | 14 (4.6%) |
| Tumor size | ||
| <5 cm | 70 (23.0%) | |
| 5–10 cm | 126 ((41.3%) | |
| >10 cm | 103 ((33.8%) | |
| NA | 6 (.,9%) | |
| Mitotic count, per 5 mm2 | ||
| <5 | 133 (43.6%) | |
| 5–10 | 62 (20.3%) | |
| >10 | 100 (32.8%) | |
| NA | 10 (3.3%) | |
| Risk Group (AFIP) | ||
| Low risk | 74 (24.3%) | |
| Intermediate risk | 54 (17.7%) | |
| High risk | 170 (55.7%) | |
| NA | 7 (2.3%) | |